Biotherapeutics development with high quality biomanufacturing criteria.
Project Status: 3 Approved without Funding
Duration in months: 36 months
Objective
Live probiotics with reliable pharmaceutical properties are qualified to become biotherapeutics. However, live biotherapeutics have a very high molecular complexity. Any small change in growth media or condition can have significant effects on the activity and potency of probiotics. Such changes are contributed by the inherent adaptability of the prokaryotic cells. The genetic, proteomic and metabolomic profile help the liability characterization of the potential biotherapeutics, furthermore moving forward the development, production, stabilization, formulation, clinical study and commercialization of live biotherapeutics. Last decades several probiotic related projects were funded in the framework of ISTC. The isolation, characterization and potential application studies of probiotics are the initial stage of biotherapeutics development. However, there are fundamental differences in product development pathway whether it is designed for nutraceutical or pharmaceutical market. The aim of this project is the development and production of stable biotherapeutics based on probiotic strains possessing radioprotective effect and antagonistic activities against certain human pathogens for the health care of working in the heavy conditions people, including aerospace, nuclear power stations, lifesavers workers in case of nuclear disasters, people subjected to nuclear weapons, irradiated cancer patients and patients under the cancer chemotherapy.
Participating Institutions
LEADING
Armenian National Agrarian University (ANAU)
PARTICIPATING
International Association for Human and Animals Health Improvement (IAHAHI)
COLLABORATOR
Lawrence Berkeley National Laboratory
COLLABORATOR
Kyungpook National University
PARTICIPATING
National Center for Disease Control and Public Health (NCDC)
